Ladenburg raised the firm’s price target on Axsome Therapeutics (AXSM) to $175 from $173 and keeps a Buy rating on the shares following the Q3 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $118 from $106 at BofA
- Axsome Therapeutics price target raised to $116 from $112 at Baird
- Axsome Therapeutics’ Strong Q3 Growth Amidst Strategic Expansions
- Axsome Therapeutics reports Q3 EPS ($1.34), consensus ($1.41)
- Axsome Therapeutics expects cash to fund operations into cash flow positivity